Biora Therapeutics, Inc. (NASDAQ:BIOR) reported select results from its BT-600 trial on July 1st confirming and expanding upon the favorable findings in the interim update provided in April. All ...
SAN DIEGO, Oct. 23, 2023 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc (BIOR). (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced an update regarding its ...
SAN DIEGO, April 30, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced completion of dosing for the ...
BT-600 is a drug/device combination delivering a liquid formulation of tofacitinib via the NaviCap™ platform for the treatment of ulcerative colitis IND application is supported by robust clinical ...
(RTTNews) - Biora Therapeutics, Inc. (BIOR) Monday announced positive data from its clinical trial of BT-600 for the potential treatment of patients with ulcerative colitis. BT-600 leverages Biora's ...
Drug-device combination leverages Biora’s NaviCap™ platform to deliver tofacitinib directly to colonic tissue as a potential treatment for ulcerative colitis BT-600 was well tolerated and met all ...
The $99.99 Monoprice BT-600 ANC headphones have budget appeal thanks to their punchy sound and competent active noise cancellation (ANC). They also work with a surprising number of Bluetooth codecs ...
Biora Therapeutics, Inc. (Nasdaq: BIOR) has shared positive topline results from its clinical trial of BT-600, an orally administered drug-device combination in development for the potential treatment ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback